Drug Trial Radar · NCT04835805
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
65
Actual
Start
May 13, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.
Conditions
- Melanoma
Interventions
BelvarafenibDrug
Twice daily (BID), continuous dosing
CobimetinibDrug
Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
NivolumabDrug
Once every 4 weeks (Q4W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Dose Limiting Toxicity (DLTs)Time frame: 28 Days from Cycle 1, Day 1
- Percentage of Participants With Adverse EventsTime frame: From Cycle 1, Day 1 Up to 4 Years
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
California Pacific Medical Center Research Institute
San Francisco, California
UCSF Helen Diller Family CCC
San Francisco, California
University of Colorado Cancer Center
Aurora, Colorado
University of Iowa
Iowa City, Iowa
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan Kettering
New York, New York
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Peter MacCallum Cancer Centre-East Melbourne
Melbourne, Victoria, Australia
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Klinikum Mannheim GmbH Universitätsklinikum
Mannheim, Germany
Universitatsklinikum Tubingen
Tübingen, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Asan Medical Center - PPDS
Seoul, South Korea
Samsung Medical Center - PPDS
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.